 |
 |
 |
New Strides in EGFR Inhibition for Non–Small Cell Lung Cancer
Suresh S. Ramalingam, MD and Heather A. Wakelee, MD
Hear about recent evidence related to identification of molecular patterns to predict response to EGFR inhibitors, learn to integrate newly approved and emerging EGFR inhibitors into the treatment plan for NSCLC, and see how to manage resistance to first-generation EGFR inhibitors.
High Suspicion of Lung Cancer: Setting the Stage with a Good Biopsy
Carl: An Interactive NSCLC Case
Momen M. Wahidi, MD, FCCP and W. Dean Wallace, MD
Molecular diagnostics and targeted therapy rely on adequate tissue biopsy. Learn from this case and better meet the needs of your multidisciplinary partners.
Work-Up of a Patient with Right Upper Lobe Mass and Metastases
Pete: An Interactive NSCLC Case
Momen M. Wahidi, MD, FCCP and W. Dean Wallace, MD
Glimpse the world of tissue processing and analysis from the pathology perspective.
TEST YOUR KNOWLEDGE: Can You Diagnose Lyman?
2-minute Case Assessment
Lyman is a 75-year-old former smoker, married, retired computer developer with a history of asthma, hypertension and diabetes, and presents with a cough. What's your diagnosis?
Pulmonologists as the Gatekeepers of Precision Medicine: How Much is Enough Tissue?
Presented by: Momen M. Wahidi, MD, FCCP and W. Dean Wallace, MD
Biomarker-driven targeted therapy of patients with NSCLC requires accurate diagnosis and staging. The pulmonary care team must acquire adequate biopsy tissue to enable histology, immunofluorescence and molecular biomarker testing. Presented in Los Angeles, California - October 2016.
NSCLC Tools and References
Overview of staging: http://www.cancer.org/cancer/lungcancer-non-smallcell/detailedguide/non-small-cell-lung-cancer-staging
Overview of diagnosis: http://www.dana-farber.org/Adult-Care/Treatment-and-Support/Non-Small-Cell-Lung-Cancer/How-We-Diagnose-Non-Small-Cell-Lung-Cancer.aspx
NCCN NSCLC Guidelines: http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf
Detterbeck FC, Mazzone PJ, Naidich DP, Bach PB. Screening for Lung Cancer: Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2013;143(5 Suppl):e78S-92S. https://www.ncbi.nlm.nih.gov/pubmed/23649455
Leighl NB, Rekhtman N, Biermann WA, et al. Molecular Testing for Selection of Patients with Lung Cancer for Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Guideline. J Clin Oncol. 2014;32(32):3673-3679. https://www.ncbi.nlm.nih.gov/pubmed/25311215
Schneider F, Smith MA, Lane MC, Pantanowitz L, Dacic S, Ohori NP. Adequacy of Core Needle Biopsy Specimens and Fine-Needle Aspirates for Molecular Testing of Lung Adenocarcinomas. Am J Clin Pathol. 2015;143(2):193-200. https://www.ncbi.nlm.nih.gov/pubmed/25596245
Silvestri GA, Gonzalez AV, Jantz MA, et al. Methods for Staging Non-Small Cell Lung Cancer: Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2013;143(5 Suppl):e211S-250S. https://www.ncbi.nlm.nih.gov/pubmed/23649440
Wahidi MM, Herth F, Yasufuku K, et al. Technical Aspects of Endobronchial Ultrasound Guided Transbronchial Needle Aspiration: CHEST Guideline and Expert Panel Report. Chest. 2016;149(3):816-835. https://www.ncbi.nlm.nih.gov/pubmed/26402427
